Eloxx Pharmaceuticals, Inc. — Q2 2022 Form 10-Q
Reporting period: Quarter and six months ended June 30, 2022. Eloxx is a clinical-stage biopharmaceutical company focused on ribosome-modulating therapies for rare diseases and cancers. It has no approved products and has not generated product or service revenue.
Financial performance and position
| Metric | Q2 2022 | Q2 2021 | Six months 2022 | Six months 2021 |
|---|---|---|---|---|
| Revenue | None | None | None | None |
| Research and development expense | $7.7 million | $5.7 million | $15.6 million | $9.8 million |
| General and administrative expense | $2.6 million | $7.4 million | $5.7 million | $11.7 million |
| Net loss | $10.6 million | $36.1 million | $22.2 million | $44.8 million |
| Basic and diluted loss per share | $0.12 | $0.54 | $0.26 | $0.84 |
| Operating cash used | Not provided for quarter | Not provided for quarter | $19.2 million | $17.5 million |
Margins are not meaningful because the company had no revenue. Q2 and first-half losses were lower year over year, principally because 2021 included $22.7 million of acquired in-process research and development expense from the Zikani acquisition. Lower general and administrative costs, including reduced stock-based compensation and personnel costs, partly offset higher R&D spending. First-half R&D expense rose 59%, driven by preclinical and clinical activity, including CFF-funded work.
Liquidity at June 30: Cash and cash equivalents were $30.0 million; restricted cash was $0.3 million. Current assets totaled $31.6 million and current liabilities $19.5 million. Total assets were $32.9 million, total liabilities $31.1 million, and stockholders’ equity $1.8 million, down from $22.4 million at year-end 2021. The accumulated deficit was $260.6 million.
Debt and funding: Hercules term-loan principal outstanding was $12.5 million, with a carrying value of $11.4 million including discounts and fees. The loan rate was 11.0% at June 30; its effective interest rate was 16.58%. The company reported compliance with debt covenants at quarter-end. It received $7.0 million from the Cystic Fibrosis Foundation (CFF) during the first half, recorded as collaboration advances, not revenue. A $50 million at-the-market equity program was available but unused as of June 30.
Business developments, outlook and risks
- ELX-02 is the company’s only clinical-stage candidate, being developed for cystic fibrosis patients with nonsense mutations. Eloxx reported positive topline results from Phase 2 monotherapy arms in November 2021 and expanded the study to evaluate ELX-02 with ivacaftor. Management said enrollment was sufficient to assess biological activity and expected data from the first four treatment arms in Q4 2022.
- The March 2022 CFF amendment provides up to $15.9 million for global Phase 2 development: $7.0 million was paid upfront and the remaining $8.9 million is milestone-dependent. Future commercialization may entail royalties and other payments to CFF.
- No specific financial guidance was provided. Management expects ongoing losses and negative operating cash flow and stated that the $30.0 million cash balance would not fund current and planned operations for at least 12 months after filing. The filing concludes substantial doubt exists about the company’s ability to continue as a going concern absent additional financing. Management may seek equity, debt, partnerships or other capital; failure to secure funding could prompt spending cuts or delays to development programs.
- Key risks include clinical efficacy, safety and enrollment uncertainty; dependence on ELX-02; financing needs and potential dilution; debt covenants and potential acceleration; and reliance on third-party research, manufacturing and clinical-trial providers. Preclinical ELX-02 testing showed renal toxicity at doses above those expected in clinical trials.
- Nasdaq had approved transfer to the Capital Market and an extension through January 2, 2023 to regain compliance with the $1.00 minimum bid-price requirement; the company warned there was no assurance it would regain compliance. No material pending legal proceedings were reported. Management concluded disclosure controls were effective as of June 30.
Investor verification points
- Confirm subsequent ELX-02 Phase 2 data, trial progress, safety findings and enrollment status against the company’s stated Q4 2022 expectation.
- Assess cash burn and financing runway, including whether new capital was raised and whether planned operations changed after filing.
- Review conditions and availability of the remaining CFF award and Hercules loan tranches, as well as debt-covenant headroom and repayment terms.
- Check Nasdaq bid-price compliance status and any listing developments after the filing.
- Track potential dilution, including the unused $50 million ATM program and outstanding options and warrants.